Arterra Bioscience
ARBS.MI · MIL
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.11 | 0.07 | -0.21 | 0.02 |
| FCF Yield | 7.11% | -0.79% | 3.47% | 4.27% |
| EV / EBITDA | 10.58 | 8.06 | 20.41 | 6.35 |
| Quality | ||||
| ROIC | 3.11% | 1.80% | 3.57% | -0.69% |
| Gross Margin | 18.55% | 20.29% | 55.03% | 57.08% |
| Cash Conversion Ratio | 1.41 | 0.45 | 1.34 | 0.95 |
| Growth | ||||
| Revenue 3-Year CAGR | 8.00% | 4.19% | 1.53% | 1.59% |
| Free Cash Flow Growth | 1,217.04% | -119.48% | 11.55% | -0.00% |
| Safety | ||||
| Net Debt / EBITDA | -2.56 | -2.39 | -5.20 | -2.70 |
| Interest Coverage | 0.00 | 456.93 | 714.96 | -13.75 |
| Efficiency | ||||
| Inventory Turnover | 1.63 | 1.15 | 1.04 | 0.34 |
| Cash Conversion Cycle | 169.10 | 213.28 | 175.55 | 380.15 |